α-Galactosylceramide
CAS No. 158021-47-7
α-Galactosylceramide ( α-GalCer; KRN7000 )
Catalog No. M26603 CAS No. 158021-47-7
α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 1455 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product Nameα-Galactosylceramide
-
NoteResearch use only, not for human use.
-
Brief Descriptionα-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.
-
Descriptionα-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.(In Vitro):Stimulation of activated Vα24+ NKT cell cultures with α-Galactosylceramide-pulsed monocyte-derived dendritic cells (Mo-DC) has antiproliferative activity against melanoma cells. Antiproliferative effects of Vα24+ NKT cells stimulated by α-Galactosylceramide-pulsed Mo-DCs via soluble mediators have antitumor activity against human melanoma. This effect is mainly due to the release of IFN-γ and, to a lesser extent, IL-12. Other cytokines, including IL-4 and IL-10, are released, but these cytokines have less antiproliferative effects .(In Vivo):α-Galactosylceramide treatment prevents spontaneous, oncogenic, or oncogene-induced primary tumor formation in mice. Consistent with a major role of IFN-γ in NKT cell-mediated tumor responses, the C-glycoside analog of α-Galactosylceramide, which preferentially stimulates IFN-γ production, was even more effective than α-galactose in preventing B16 melanoma metastasis. Ceramides are more effective . α-Galactosylceramide showed potent antitumor activity and stimulated lymphocyte proliferation (LP) in mouse allogeneic mixed lymphocyte reaction (MLR) .
-
Synonymsα-GalCer; KRN7000
-
PathwayOthers
-
TargetOther Targets
-
RecptorGPR119
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number158021-47-7
-
Formula Weight858.3
-
Molecular FormulaC50H99NO9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ning Y, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol. 2008;155(7):1056-1065.
molnova catalog
related products
-
3-Hydroxybenzaldehyd...
3-Hydroxybenzaldehyde is a compound useful in organic synthesis.
-
Methylene Blue trihy...
A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster.
-
SCS
SCS a potent selective inhibitor of α2β1γ1θ GABA(A) receptors with a maximum inhibition of 56+/-5% and an IC50 of 32 nM.